US20160376259A1 - Methods for Preparing Oltipraz - Google Patents

Methods for Preparing Oltipraz Download PDF

Info

Publication number
US20160376259A1
US20160376259A1 US14/823,256 US201514823256A US2016376259A1 US 20160376259 A1 US20160376259 A1 US 20160376259A1 US 201514823256 A US201514823256 A US 201514823256A US 2016376259 A1 US2016376259 A1 US 2016376259A1
Authority
US
United States
Prior art keywords
reaction
added
container
stirred
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/823,256
Other languages
English (en)
Inventor
Bomi P. Framroze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supportive Therapeutics Ag
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Assigned to ST IP HOLDING AG reassignment ST IP HOLDING AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FRAMROZE, BOMI P.
Priority to EP16813869.1A priority Critical patent/EP3313835A4/en
Priority to JP2017565999A priority patent/JP6773693B2/ja
Priority to KR1020187002139A priority patent/KR20180022838A/ko
Priority to AU2016283082A priority patent/AU2016283082B2/en
Priority to CA2989228A priority patent/CA2989228A1/en
Priority to PCT/IN2016/050197 priority patent/WO2016207914A2/en
Priority to MA042264A priority patent/MA42264A/fr
Publication of US20160376259A1 publication Critical patent/US20160376259A1/en
Priority to US16/041,282 priority patent/US20190084971A1/en
Priority to US16/784,915 priority patent/US20200172522A1/en
Priority to US16/854,480 priority patent/US10968207B2/en
Priority to US17/210,049 priority patent/US20210206752A1/en
Assigned to Foley Hoag LLP reassignment Foley Hoag LLP LIEN (SEE DOCUMENT FOR DETAILS). Assignors: ST IP HOLDING AG
Assigned to ZPNE GROUP GMBH reassignment ZPNE GROUP GMBH MERGER BY ACQUISITION Assignors: ST IP HOLDING AG
Assigned to SUPPORTIVE THERAPEUTICS AG reassignment SUPPORTIVE THERAPEUTICS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZPNE GROUP GMBH
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • Oltipraz 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, depicted in Formula I, below, was originally developed as an anti-schistosomal drug that eliminates parasitic worms. Later, it was discovered that oltipraz is a chemopreventive agent. The drug also has other known and unknown uses in the medical field.
  • the invention relates to a method comprising the steps of:
  • the solution is added over a period of time of about 30 minutes while warming the first container to a temperature of about 22° C.; and the second solvent is a mixture of tetrahydrofuran and 1,4-dioxane; and
  • the invention relates to any of the methods described herein, wherein the first base is sodium pentanoate or potassium t-butoxide.
  • the invention relates to any of the methods described herein, wherein the method is a method of synthesizing
  • the invention relates to a method of synthesizing oltipraz, comprising the steps of:
  • the invention relates to any of the methods described herein, wherein the purity of the oltipraz produced by the claimed methods is greater than 97%, greater than 98%, or greater than 99%, as determined by gas chromatography.
  • the invention relates to any of the methods described herein, wherein the overall yield of oltipraz from
  • the invention relates to any of the methods described herein, wherein the overall yield of oltipraz from
  • the invention relates to an improved method of synthesizing oltipraz.
  • the method involves Step 2 or Step 3 (or both Step 2 and Step 3 in succession) as depicted in Scheme 1.
  • the invention relates to any one of the methods described herein, wherein Step 2 does not involve sodium hydride.
  • the invention relates to any one of the methods described herein, wherein the yield of Step 2 is greater than 80%, greater than 81%, greater than 82%, greater than 83%, greater than 84%, greater than 85%, greater than 86%, greater than 87%, greater than 88%, greater than 89%, greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, or greater than 99%.
  • the invention relates to any one of the methods described herein, wherein the overall yield of Step 2 and Step 3 is greater than 21%, greater than 22%, greater than 23%, greater than 24%, greater than 25%, greater than 26%, greater than 27%, greater than 28%, greater than 29%, or greater than 30%.
  • the invention relates to any one of the methods described herein, wherein the purity of the oltipraz produced by the claimed methods is greater than 97%, greater than 98%, or greater than 99%, as determined by gas chromatography.
  • the invention relates to any one of the methods described herein, wherein the overall yield of Step 2 and Step 3 is greater than 21%, and the purity of the resulting oltipraz is greater than 97%, as determined by gas chromatography.
  • the invention relates to a method comprising the steps of:
  • the solution is added over a period of time of about 30 minutes while warming the first container to a temperature of about 22° C.; and the second solvent is a mixture of tetrahydrofuran and 1,4-dioxane; and
  • the invention relates to any of the methods described herein, wherein the first solvent is tetrahydrofuran.
  • the invention relates to any of the methods described herein, wherein the first solvent is a mixture of tetrahydrofuran and 1,4-dioxane. In certain embodiments, the invention relates to any of the methods described herein, wherein the first solvent is about a 5:1, about a 4:1, or about a 3:1 mixture by volume of tetrahydrofuran and 1,4-dioxane. In certain embodiments, the invention relates to any of the methods described herein, wherein the first solvent is about a 4:1 mixture by volume of tetrahydrofuran and 1,4-dioxane.
  • the invention relates to any of the methods described herein, wherein the first base is sodium pentanoate or potassium t-butoxide.
  • the invention relates to any of the methods described herein, wherein the concentration of the first base in the first solvent is from about 1.0 M to about 1.8 M.
  • the invention relates to any of the methods described herein, wherein the concentration of the first base in the first solvent is about 1.0 M, about 1.2 M, about 1.4 M, about 1.6 M, or about 1.8 M. In certain embodiments, the invention relates to any of the methods described herein, wherein the concentration of the first base in the first solvent is about 1.4 M.
  • the invention relates to any of the methods described herein, wherein the mole ratio of first base to methyl propionate is from about 3:1 to about 1:1. In certain embodiments, the invention relates to any of the methods described herein, wherein the mole ratio of first base to methyl propionate is about 3:1, about 2:1, or about 1:1. In certain embodiments, the invention relates to any of the methods described herein, wherein the mole ratio of first base to methyl propionate is about 1:1.
  • the invention relates to any of the methods described herein, wherein the concentration of
  • the invention relates to any of the methods described herein, wherein the concentration of
  • the invention relates to any of the methods described herein, wherein the concentration of
  • the invention relates to any of the methods described herein, wherein the mole ratio of methyl propionate to
  • the invention relates to any of the methods described herein, wherein the mole ratio of methyl propionate to
  • the invention relates to any of the methods described herein, wherein the mole ratio of methyl propionate to
  • the invention relates to any of the methods described herein, wherein the second solvent is from about a 1.2:1 to about a 0.8:1 mixture by volume of tetrahydrofuran and 1,4-dioxane. In certain embodiments, the invention relates to any of the methods described herein, wherein the second solvent is about a 1.2:1, about a 1:1, or about a 0.8:1 mixture by volume of tetrahydrofuran and 1,4-dioxane. In certain embodiments, the invention relates to any of the methods described herein, wherein the second solvent is about a 1:1 mixture by volume of tetrahydrofuran and 1,4-dioxane.
  • the invention relates to any of the methods described herein, wherein the first period of time is from about 2 h to about 10 h. In certain embodiments, the invention relates to any of the methods described herein, wherein the first period of time is about 2 h, about 3 h, about 4 h, about 5 h, about 6 h, about 7 h, about 8 h, about 9 h, or about 10 h. In certain embodiments, the invention relates to any of the methods described herein, wherein the first period of time is about 6 h.
  • the invention relates to any of the methods described herein, wherein the method is a method of synthesizing
  • the invention relates to any of the methods described herein, wherein the method is a method of synthesizing
  • the invention relates to any of the methods described herein, wherein the method is a method of synthesizing
  • the invention relates to any of the methods described herein, wherein the method consists essentially of steps (a)-(f).
  • the invention relates to a method comprising the steps of:
  • the invention relates to a method comprising the steps of:
  • the invention relates to any of the methods described herein, wherein the concentration of P 2 S 5 in the first quantity of toluene is from about 0.2 M to about 0.5 M. In certain embodiments, the invention relates to any of the methods described herein, wherein the concentration of P 2 S 5 in the first quantity of toluene is about 0.2 M, about 0.25 M, about 0.3 M, about 0.35 M, about 0.4 M, about 0.45 M, or about 0.5 M.
  • the invention relates to any of the methods described herein, wherein P 2 S 5 and the first quantity of toluene are combined in the second container under an inert atmosphere. In certain embodiments, the invention relates to any of the methods described herein, wherein P 2 S 5 and the first quantity of toluene are combined in the second container under a nitrogen atmosphere.
  • the invention relates to any of the methods described herein, wherein the volume ratio of the first quantity of toluene to the first quantity of water is about 12:1, about 10:1, or about 8:1. In certain embodiments, the invention relates to any of the methods described herein, wherein the volume ratio of the first quantity of toluene to the first quantity of water is about 10:1.
  • the invention relates to any of the methods described herein, wherein the phase transfer catalyst is a tetraalkylammonium salt or a tetraalkylphosphonium salt. In certain embodiments, the invention relates to any of the methods described herein, wherein the phase transfer catalyst is a tetrabutylphosphonium salt. In certain embodiments, the invention relates to any of the methods described herein, wherein the phase transfer catalyst is tetrabutylphosphonium halide. In certain embodiments, the invention relates to any of the methods described herein, wherein the phase transfer catalyst is tetrabutylphosphonium chloride.
  • the invention relates to any of the methods described herein, wherein the concentration of
  • the invention relates to any of the methods described herein, wherein the concentration of
  • toluene in the second quantity of toluene is about 0.2 M, about 0.3 M, or about 0.4 M.
  • the invention relates to any of the methods described herein, wherein the mole ratio of P 2 S 5 to
  • the invention relates to any of the methods described herein, wherein the mole ratio of P 2 S 5 to
  • the invention relates to any of the methods described herein, wherein the second period of time is from about 2 h to about 10 h. In certain embodiments, the invention relates to any of the methods described herein, wherein the second period of time is about 2 h, about 3 h, about 4 h, about 5 h, about 6 h, about 7 h, about 8 h, about 9 h, or about 10 h. In certain embodiments, the invention relates to any of the methods described herein, wherein the second period of time is about 6 h.
  • the invention relates to any of the methods described herein, wherein the
  • the invention relates to any of the methods described herein, wherein the mole ratio of
  • the invention relates to any of the methods described herein, wherein the mole ratio of
  • the invention relates to any of the methods described herein, wherein the mole ratio of
  • the invention relates to any of the methods described herein, wherein the mole ratio of
  • the invention relates to any of the methods described herein, wherein the method is a method of synthesizing oltipraz.
  • the invention relates to any of the methods described herein, wherein the overall yield of oltipraz from
  • the invention relates to any of the methods described herein, wherein the purity of the oltipraz produced by the claimed methods is greater than 97%, greater than 98%, or greater than 99%, as determined by gas chromatography.
  • the invention relates to any of the methods described herein, wherein the overall yield of oltipraz from
  • the invention relates to any of the methods described herein, wherein the method consists essentially of steps (i)-(iv).
  • the invention relates to any of the methods described herein, wherein the method consists essentially of steps (a)-(f) and steps (i)-(iv).
  • the invention relates to any one of the methods described herein, further comprising the steps outlined in any other method described herein.
  • the invention relates to the use of any one of the compounds described herein in the manufacture of a medicament.
  • the compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids.
  • Optical isomers may be prepared, for example, by resolving a racemic mixture. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers. Racemates, and Resolutions (John Wiley & Sons, 1981).
  • the synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization.
  • a method such as column chromatography, high pressure liquid chromatography, or recrystallization.
  • further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art.
  • the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • the solvents, temperatures, reaction durations, etc. delineated herein are for purposes of illustration only and one of ordinary skill in the art will recognize that variation of the reaction conditions can produce the desired bridged macrocyclic products of the present invention.
  • Synthetic chemistry transformations useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R.
  • the present invention is further illustrated by the following Example which should not be construed as limiting in any way.
  • the Examples and discoveries described herein are representative. As such, the studies and results described in the Examples section herein may be used as a guideline.
  • Methyl propionate 64 g+893 g; Lot#11-2713-56+11-2713-57+R11-1913-101
  • ST-602 (from 1 kg of ST-601 (SM), 1 eq); Lot#2463-52-2
  • Aim Establish baseline for Step 2 using NaH as the base.
  • Aim Carry out Step 3 to study cyclization of crude mixture from potassium t-butoxide condensation.
  • Aim Carry out Step 3 to study cyclization of crude mixture from sodium pentanoate condensation.
  • Aim Carry out Step 3 to study cyclization of crude mixture from sodium pentanoate condensation.
  • Aim Carry out Step 3 in toluene and water under reflux using an ammonium salt as a phase transfer catalyst
  • Aim Carry out Step 3 in toluene and water under reflux using an ammonium salt as a phase transfer catalyst
  • Aim Carry out Step 3 in toluene and water under reflux using an ammonium salt as a phase transfer catalyst
  • Aim Carry out Step 3 in toluene and water under reflux using an ammonium salt as a phase transfer catalyst
  • Aim Carry out Step 3 in toluene and water under reflux using an ammonium salt as a phase transfer catalyst

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US14/823,256 2015-06-25 2015-08-11 Methods for Preparing Oltipraz Abandoned US20160376259A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP16813869.1A EP3313835A4 (en) 2015-06-25 2016-06-24 PROCESS FOR THE PREPARATION OF OLTIPRAZ
JP2017565999A JP6773693B2 (ja) 2015-06-25 2016-06-24 オルチプラズを調製する方法
KR1020187002139A KR20180022838A (ko) 2015-06-25 2016-06-24 올티프라즈를 제조하기 위한 방법
AU2016283082A AU2016283082B2 (en) 2015-06-25 2016-06-24 Methods for preparing oltipraz
CA2989228A CA2989228A1 (en) 2015-06-25 2016-06-24 Methods for preparing oltipraz
PCT/IN2016/050197 WO2016207914A2 (en) 2015-06-25 2016-06-24 Methods for preparing oltipraz
MA042264A MA42264A (fr) 2015-06-25 2016-06-24 Procédé de préparation d'oltipraz
US16/041,282 US20190084971A1 (en) 2015-06-25 2018-07-20 Methods for preparing oltipraz
US16/784,915 US20200172522A1 (en) 2015-06-25 2020-02-07 Methods for preparing oltipraz
US16/854,480 US10968207B2 (en) 2015-06-25 2020-04-21 Methods for preparing oltipraz
US17/210,049 US20210206752A1 (en) 2015-06-25 2021-03-23 Methods for preparing oltipraz

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1891DE2015 2015-06-25
IN1891/DEL/2015 2015-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/041,282 Continuation US20190084971A1 (en) 2015-06-25 2018-07-20 Methods for preparing oltipraz

Publications (1)

Publication Number Publication Date
US20160376259A1 true US20160376259A1 (en) 2016-12-29

Family

ID=57601888

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/823,256 Abandoned US20160376259A1 (en) 2015-06-25 2015-08-11 Methods for Preparing Oltipraz
US16/041,282 Abandoned US20190084971A1 (en) 2015-06-25 2018-07-20 Methods for preparing oltipraz
US16/784,915 Abandoned US20200172522A1 (en) 2015-06-25 2020-02-07 Methods for preparing oltipraz
US16/854,480 Active US10968207B2 (en) 2015-06-25 2020-04-21 Methods for preparing oltipraz
US17/210,049 Abandoned US20210206752A1 (en) 2015-06-25 2021-03-23 Methods for preparing oltipraz

Family Applications After (4)

Application Number Title Priority Date Filing Date
US16/041,282 Abandoned US20190084971A1 (en) 2015-06-25 2018-07-20 Methods for preparing oltipraz
US16/784,915 Abandoned US20200172522A1 (en) 2015-06-25 2020-02-07 Methods for preparing oltipraz
US16/854,480 Active US10968207B2 (en) 2015-06-25 2020-04-21 Methods for preparing oltipraz
US17/210,049 Abandoned US20210206752A1 (en) 2015-06-25 2021-03-23 Methods for preparing oltipraz

Country Status (7)

Country Link
US (5) US20160376259A1 (enrdf_load_stackoverflow)
EP (1) EP3313835A4 (enrdf_load_stackoverflow)
JP (1) JP6773693B2 (enrdf_load_stackoverflow)
KR (1) KR20180022838A (enrdf_load_stackoverflow)
AU (1) AU2016283082B2 (enrdf_load_stackoverflow)
CA (1) CA2989228A1 (enrdf_load_stackoverflow)
MA (1) MA42264A (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160376259A1 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
AU2017323504A1 (en) * 2016-09-12 2019-05-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
CN109996563A (zh) * 2016-09-12 2019-07-09 St知识产权控股公司 4-甲基-5-(吡嗪-2-基)-3h-1,2-二硫杂环戊烯-3-硫酮的制剂、味道改良的制剂及其制备和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171985C (nl) * 1976-02-10 1983-06-16 Rhone Poulenc Ind Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen.
AU6462500A (en) * 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
CN1192775C (zh) 2000-04-07 2005-03-16 金相建 吡噻硫酮在制备预防和治疗肝维化和肝硬化药物中的用途及含有其的药物组合物
EP1355536B1 (en) * 2000-11-20 2012-01-11 Applied Food Sciences, Inc. A method for enhancing post-processing content of beneficial compounds in beverages naturally containing same
KR100491318B1 (ko) * 2002-11-26 2005-05-24 씨제이 주식회사 올티프라즈(Ｏｌｔｉｐｒａｚ) 제조방법
KR100629771B1 (ko) 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
US20160376259A1 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz

Also Published As

Publication number Publication date
JP6773693B2 (ja) 2020-10-21
KR20180022838A (ko) 2018-03-06
EP3313835A2 (en) 2018-05-02
US20210206752A1 (en) 2021-07-08
EP3313835A4 (en) 2019-01-09
US10968207B2 (en) 2021-04-06
MA42264A (fr) 2018-05-02
US20200247791A1 (en) 2020-08-06
AU2016283082A1 (en) 2018-01-18
US20200172522A1 (en) 2020-06-04
JP2018520134A (ja) 2018-07-26
US20190084971A1 (en) 2019-03-21
AU2016283082B2 (en) 2020-11-26
CA2989228A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
WO2016207914A2 (en) Methods for preparing oltipraz
US10968207B2 (en) Methods for preparing oltipraz
CN110105193B (zh) 一种2-卤-5-溴苯甲酸的合成方法
JP5384753B2 (ja) アスタキサンチンジメチルジスクシネートを製造するための方法
JP7547414B2 (ja) シス－アルコキシ置換スピロ環式１－ｈ－ピロリジン－２，４－ジオン誘導体の製造方法
CA2960473A1 (en) Processes for the preparation of tadalafil and intermediates thereof
EP3577099B1 (en) A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
US11136277B2 (en) Process for the production of beta-springene
EP2655325A1 (en) 2-(alkoxy or aryloxy carbonyl)-4-methyl-6-(2,6,6-trimethylcyclohex-1-enyl)hex-2-enoic acid compounds, its preparation and use
US8492579B2 (en) Method for producing astaxanthin dimethyldisuccinate
JP2743461B2 (ja) １―メチル―３―アルキル―５―ピラゾールカルボン酸エステル類の製造法
US3652643A (en) Methyl 3 3-dichloro-1-lower alkoxy-2-oxo cyclopentane carboxylate
KR20170018854A (ko) 3-클로로-2-비닐페놀의 제조 방법
JP7702969B2 (ja) アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの連続製造方法
WO2008075468A1 (ja) ２－イソプロペニル－５－メチル－４－ヘキセン－１－イル ３－メチル－２－ブテノアートの製造方法
TW202302550A (zh) 製備４－氧代四氫呋喃－２－羧酸烷基酯之方法
JP6660393B2 (ja) ４−シアノピペリジン塩酸塩を調製する方法
TW202302551A (zh) 用於製備４－側氧四氫呋喃－２－羧酸烷基酯之方法
Liu et al. 4-(Nitro)-diphenylammonium triflate (NDPAT) catalysed esterification of carboxylic acids with alcohols
EP1948584B1 (en) Process for the preparation of cyclopentanone derivatives
IL299857A (en) 4-furanamides and a method for their production
Maggio et al. The Reactivity of 4’-Substituted Spiro [Isoindole-1, 3’-pyrazoles] Derivatives: Substitution/Elimination Reactions and Access to Biaryl Derivatives
Hernández-Ibinarriaga et al. Nucleophilic Addition of Potassium O-Ethyl Dithiocarbonate to Baylis-Hillman Adducts Using 9-BBN as Catalyst
HK1200452A1 (en) Processes for the preparation of 6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide and of its precursors
HK1200452B (en) Processes for the preparation of 6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide and of its precursors

Legal Events

Date Code Title Description
AS Assignment

Owner name: ST IP HOLDING AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FRAMROZE, BOMI P.;REEL/FRAME:036574/0366

Effective date: 20150907

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: FOLEY HOAG LLP, MASSACHUSETTS

Free format text: LIEN;ASSIGNOR:ST IP HOLDING AG;REEL/FRAME:060520/0681

Effective date: 20220614

AS Assignment

Owner name: ZPNE GROUP GMBH, SWITZERLAND

Free format text: MERGER BY ACQUISITION;ASSIGNOR:ST IP HOLDING AG;REEL/FRAME:071925/0865

Effective date: 20250331

AS Assignment

Owner name: SUPPORTIVE THERAPEUTICS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZPNE GROUP GMBH;REEL/FRAME:071622/0178

Effective date: 20250701